MetLife’s second quarter results were marked by broad-based earnings growth, with market participants rewarding the company’s performance as shares rose notably after the announcement. Management attributed the positive momentum to strong underwriting across all segments, increased international sales, and disciplined expense controls. CEO Michel Khalaf pointed to the impact of MetLife’s “New Frontier strategy,” which leverages recurring revenue streams and a diverse global portfolio, emphasizing, “We reported adjusted earnings of approximately $1.6 billion or $2.43 per share.” The quarter also benefited from favorable mortality experience in the Group Benefits segment and continued investment in technology to drive productivity.
Is now the time to buy MET? Find out in our full research report (it’s free for active Edge members).
MetLife (MET) Q2 CY2026 Highlights:
- Revenue: $19.08 billion vs analyst estimates of $19.5 billion (6.4% year-on-year growth, 2.2% miss)
- Adjusted EPS: $2.43 vs analyst estimates of $2.29 (6.2% beat)
- Market Capitalization: $61.51 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From MetLife’s Q2 Earnings Call
-
Ryan Krueger (KBW) asked about inorganic growth, especially in asset management and group businesses. CEO Michel Khalaf reaffirmed disciplined M&A, with focus on complementary capabilities, not transformational deals.
-
Pablo Singzon (JPMorgan) pressed for details on mortality experience outside of Group Life. Head of U.S. Business Ramy Tadros explained improvements are stronger in working-age populations, with retiree segments performing in line with expectations.
-
Suneet Kamath (Jefferies) sought clarity on the pension risk transfer (PRT) market outlook. Tadros acknowledged first-half softness but pointed to a strong second-half pipeline and stated, “the macro picture is extremely positive.”
-
Tom Gallagher (Evercore) inquired about potential Latin American M&A. Khalaf declined to comment on market speculation but emphasized disciplined capital deployment and satisfaction with current LatAm growth.
-
Wilma Burdis (Raymond James) asked about private equity allocations. CFO John McCallion explained the gradual reduction is due to higher interest rates and that distributions are expected to outpace new investments over time.
Catalysts in Upcoming Quarters
In the next few quarters, the StockStory team will monitor (1) the pace of international sales, especially in Asia and Latin America, (2) MetLife’s ability to maintain its direct expense ratio amid ongoing technology investments and acquisitions, and (3) trends in pension risk transfer and asset management flows. We will also watch for any normalization in mortality experience and variability in investment income, which could influence both near-term results and management’s capital deployment strategy.
MetLife currently trades at $96.82, in line with $96.26 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
